Connect with us


UCB Receives Approval from the EMA for its Treatment against Hidradenitis Suppurativa

The European Medicines Agency (EMA) is close to authorizing UCB’s new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be the first IL-17A and IL-17F inhibitor approved in the EU for this condition. If approved, it would mark UCB’s fourth marketing authorization in three years, expanding its indications beyond psoriasis and arthritis.




The European Medicines Agency (EMA), one step closer to granting authorization to a new UCB treatment. The Belgian biopharmaceutical company has obtained a positive assessment from the Committee for Medicinal Products for Human Use (Chmp) of the EMA for the marketing of Bimzelx, a compound with which to treat hidradenitis suppurativa in adult patients who respond inadequately to conventional treatments.

If approved by the European Commission, this drug will be the first IL-17A and IL-17F inhibitor approved in the European Union (EU) to treat hidradenitis suppurativa. It is a chronic inflammatory skin pathology that is expressed in the form of abscesses, fistulas with pus secretion and nodules, generally in the armpits, groin and buttocks. It affects 1% of the population in almost all countries in which there are studies.

“If approved by the European Commission, it would be the fourth marketing authorization for this treatment in the last three years and would be added to the existing indications that the therapy already has for moderate to severe plaque psoriasis.” , active psoriatic arthritis and active axial spondyloarthritis,” Emmanuel Caeymaex, executive vice president of Immunology and director in the United States of UCB, states in a company statement.

Read more about UCB new treatment and find the most important business news from around the world with our companion app Born2Invest.

UCB has had 1,014 participants diagnosed with hidradenitis suppurativa to test its medication

The positive resolution of the Chmp on Bimzelx against hidradenitis suppurativa is based on the findings of the phase III studies Be Heard I and Be Heard II, in which the efficacy and safety of the treatment in adults with the aforementioned disease was evaluated. The data reflect that UCB treatment, compared to placebo, resulted in significant improvements in hidradenitis suppurativa symptoms at week sixteen , which was considered the primary endpoint in the study. Furthermore, responses lasted until week 48.

Be Heard I and Be Heard II are phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of the Belgian pharmaceutical compound in adults with moderate to severe hidradenitis suppurativa. . The two studies had 1,014 diagnosed participants .

UCB is a biopharmaceutical company that has nearly 9,000 employees in forty countries, in addition to revenues of €5.3 billion in 2023.


(Featured image by Nastia Dulhiier via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.